Abdulrahman Nasiri: Most Important Concepts and the Clinical Shift the COBRRA Trial Brings to Practice
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared a post on LinkedIn:
”In preparation for my upcoming Grand Rounds presentation, I’ve put together these slides translating the recent COBRRA trial (NEJM 2026) titled:
‘Settling the DOAC Debate in Acute VTE’.
For years, major clinical guidelines haven’t recommended one DOAC over another due to a lack of head-to-head randomized trials.
Here are the most important concepts and the clinical shift this trial brings to our practice:
- Identical Efficacy: Both Apixaban and Rivaroxaban demonstrated an identical ~1% rate of recurrent VTE.
- Superior Safety: Apixaban cut the risk of clinically relevant bleeding by more than half and drove an 84% reduction in major bleeding.
- The Dosing Hypothesis: Why the difference? The bleeding divergence explodes in the first 3 weeks.
Rivaroxaban requires a high-dose induction phase that is three times longer than Apixaban (21 days vs. 7 days).
I am sharing the presentation here. Please feel free to use and adapt these slides for your own reference, clinical discussions, or teaching.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 15:01Augustina Isioma Ikusemoro: The Most Misunderstood Cause of a Prolonged APTT in the Laboratory
-
Apr 15, 2026, 14:55Donald Correll: Key Risk Factors for Venous Thromboembolism
-
Apr 15, 2026, 14:48Fadwa Said Abdelazim: Is Vaping Really ‘Safer’ for the Blood Than Smoking?
-
Apr 15, 2026, 14:42Augustina Isioma Ikusemoro: An Underrecognized Cause of Severe Thrombocytopenia Following Transfusion
-
Apr 15, 2026, 14:42Caitlin Raymond: Augmented Intelligence Enhancing Human Capability Without Replacement
-
Apr 15, 2026, 14:39Pooja Choradia: Recognizing Pulmonary Embolism in Pregnancy Before It Is Too Late
-
Apr 15, 2026, 14:38Alessandra Bosch։ Understanding Haemostasis in Children and Its Challenges
-
Apr 15, 2026, 14:29Joseph Caprini: The Future of VTE Care Is Shifting from Static Risk to Digital Twins
-
Apr 15, 2026, 14:25Prince Alfred Singh։ Understanding Antithrombin III Deficiency as a High-Risk Thrombophilia